US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
Executive Summary
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.